SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on Middle East supply concerns, including reported tanker and energy-infrastructure attacks, while traders also weigh Ukrainian strikes on Russian oil assets. The community is split between expecting supply risks to keep oil elevated and betting that diplomacy, supply relief, or an overextended rally will bring a pullback.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A European Medicines Agency committee recommendation for Lillys Foundayo obesity pill is fueling a breakout to fresh highs, with traders also focused on the upcoming earnings report. Bulls see the pill as expanding Lillys obesity-market reach, while skeptics question whether the gains will hold and point to competition from Novo Nordisk.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp, extended semiconductor selloff has put SOXX in focus, with traders debating whether fears over AI spending returns, debt and crowded positioning signal a deeper downturn or an oversold bounce. Some see upcoming chip and hyperscaler earnings as a test of demand and capex, while others remain cautious about the sectors technical weakness.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics is drawing attention after RAP-219 met the primary and secondary endpoints in a Phase 2 trial for acute bipolar mania. Traders are divided: bulls view the results as proof of concept and note plans for Phase 3, while skeptics question the modest efficacy and point to agitation and discontinuation concerns as the initial rally faded.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results and outlook are drawing attention, with traders focusing on strong revenue growth, AI-related demand, and recurring royalties from its Vertical Power Delivery licensing business. The reaction is broadly bullish after the shares rise, though some traders question the valuation and weigh the earnings details against capacity constraints and uncertainty around how durable royalty revenue will be.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly results beat expectations and management raised its outlook, but shares fell as traders focused on rising costs, weaker free cash flow, and a loss in the insurance business. Bulls view the selloff as an overreaction to a strong report, while bears point to cost and execution concerns and continued technical weakness.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis

(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM...

BridgeBio Pharma Becomes Oversold (BBIO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis DayPR NewswirePALO ALTO, Calif., Oct. 6, 2026October 6 YouTube premiere featuring Sway...

Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence

ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB inked deals with the Trump administration on Monday.&nbsp;</li><li>The nine companies pledged at least $19.6 billion in near-term U.S. factory spending.</li><li>U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move.</li></ul>President Donald Trump on Monday said nine mid-sized drugmakers have agreed to lower drug prices in the U.S., including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), CSL, Kyowa Kirin, Sun Pharma, Teva (TEVA), and UCB.Under the deals, they would charge Americans no more than the lowest price paid in other rich countries, similar to big-pharma companies that inked similar deals with the Trump Administration last year. The medicines treat conditions such as cancer, Parkinson’s, hemophilia, eye disease, liver disease, and skin problems. The same rule would also apply to new drugs launched by these companies later.The nine companies pledged at least $19.6 billion in near-term U.S. factory spending. Some also said they will donate drug ingredients to a U.S. emergency reserve.U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move. Teva Pharmaceutical closed down 1.1%, then gained 2% in after-hours trading. BeOne Medicines finished down about 2%, and held that level after the close. BridgeBio was essentially flat in the regular session and ticked slightly higher after hours. Alcon shares were little changed.<h2 class="st-heading-2">Trump’s Pricing Push</h2>The fresh deals follow a push that began in 2025. Trump signed an order seeking “most-favored-nation” prices, then sent letters to 17 of the world’s largest drugmakers. He warned of tariffs on imports if they did not cut U.S. prices.Pfizer went first in September 2025. AstraZeneca and EMD Serono followed. In November, Eli Lilly and Novo Nordisk agreed to steep cuts on popular weight-loss and diabetes shots sold through TrumpRx.gov and at $50 a month for many Medicare patients.In December, nine more giants signed on in one day: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. Johnson &amp; Johnson and AbbVie followed in January. Regeneron was the last among the companies targeted by Trump to ink a most-favored-nation deal, after signing in April. Those earlier pacts mixed lower Medicaid prices, cash discounts on a government website, factory spending in the United States, and relief from drug tariffs.The White House said on Monday that earlier deals plus the fresh nine now cover 26 companies and 89% of the branded drug market. Every state Medicaid program would get those lower prices. Officials said that would save billions. The president’s economic team estimates all of the deals will save $600 billion over 10 years.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TEVA was bullish. Sentiment around BBIO and ONC, however, was neutral while ALC was bearish.Among those who inked deals with the administration on Monday, <a href="https://stocktwits.com/symbol/TEVA">TEVA</a> gained 16% year-to-date and <a href="https://stocktwits.com/symbol/ONC">ONC</a> 18%. ALC has fallen 9% year-to-date, while <a href="https://stocktwits.com/symbol/BBIO">BBIO</a> traded flat. 'Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-jumps-as-cybercabs-hit-texas-robotaxi-roster-ahead-of-launch-event/cZYz5JWRJsy">TSLA Stock Jumps as Cybercabs Hit Texas Robotaxi Roster Ahead Of Launch Event</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Brandon Wiley, Pharm D., pharmacist at Wiley Pharmacy in Lancaster, works at Wiley Pharmacy. Photo by Susan L. Angstadt 1/28/2015 (Photo By Susan L. Angstadt/MediaNews Group/Reading Eagle via Getty Images)

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries. 

Alcon Inc. - Registered Shares

BeOne Medicines Ltd - ADR

Teva- Pharmaceutical Industries Ltd. - ADR

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$68.28
Prev Close	$67.94
Open	$67.96
Dividend Yield	0.00%
50-Day Moving Average	$72.61
Beta	1.20
Avg. Volume	2.78M
PE Ratio	-19.04

52-Week High	$93.42
52-Week Low	$52.75
Market Capitalization	$13.28B
EPS (Annual)	-$3.79
Price to Book	-5.27
Revenue Per Employee	$598,421.93

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBIO Fundamentals